Bayesian Network Modeling: The Future of Pulmonary Arterial Hypertension Risk Stratification Through the PHORA Initiative

What’s new in pulmonary hypertension clinical research: lessons from the best abstracts at the 2020 American Thoracic Society International Conference

“…Dr. Benza’s ATS presentation highlighted an updated PHORA 2.0 model. 2 Avoiding the known limitations of registry data, PHORA 2.0 was developed using large datasets aggregated from contemporary clinical trials. Rather than anchoring to the same REVEAL-based input parameters and cut-points, the PHORA 2.0 model was built by incorporating both empirical methods and domain knowledge to select and refine variables with the greatest predictive power.…”

“…Five major research themes emerged: standardizing diagnosis and management of PH, improving risk assessment in pulmonary arterial hypertension (PAH), evaluating biomarkers of disease activity, understanding metabolic dysregulation across the spectrum of PH, and advancing knowledge in chronic thromboembolic PH (CTEPH). Table 1 provides a list of the abstracts and presenters featured during the session [1][2][3][4][5][6][7] . Notably, some of these studies have already made it to publication in peer-reviewed journals [8][9][10][11] .…”

“…This virtual mini-symposium took place on October 21, 2020, in lieu of the annual in-person ATS International Conference which was cancelled due to the COVID-19 pandemic. Seven clinical research abstracts were selected for presentation in the session, which encompassed five major themes: (1) standardizing diagnosis and management of pulmonary hypertension, (2) improving risk assessment in pulmonary arterial hypertension, (3) evaluating biomarkers of disease activity, (4) understanding metabolic dysregulation across the spectrum of pulmonary hypertension, and (5) advancing knowledge in chronic thromboembolic pulmonary hypertension. Focusing on these five thematic contexts we review the current state of knowledge, summarize presented research abstracts, appraise their significance and limitations, and then discuss relevant future directions in pulmonary hypertension clinical research.…”

“…Table 1 provides a list of the abstracts and presenters featured during the session. 1 – 7 Notably, some of these studies have already made it to publication in peer-reviewed journals. 8 – 11…”

“…Table 1 provides a list of the abstracts and presenters featured during the session. [1][2][3][4][5][6][7] Notably, some of these studies have already made it to publication in peerreviewed journals. [8][9][10][11] In the sections that follow, we will focus on the five virtual mini-symposium themes by reviewing existing contextrelevant knowledge, summarizing the abstracts presented, evaluating their strengths and limitations, and highlighting their potential clinical implications.…”